Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma Clinical Trials in Columbus, Ohio

Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma